Madrigal Pharmaceuticals down after wider-than-expected Q4 net loss

Madrigal Pharmaceuticals

19/02/2026 14:11

** Shares of drugmaker Madrigal Pharmaceuticals MDGL.O down 6% at $462.10 premarket

** Co reports Q4 loss of $2.57 per share vs analysts' estimated loss of 40 cents per share - LSEG data

** MDGL posts Q4 net revenue of $321.1 million vs estimates of $312.5 million

** Truist Securities says "the 12% Q4 and Q3 revenue growth reflecting consistent progress should aid in providing investor confidence that the company can continue to execute on Rezdiffra"

** As of December 31, Madrigal had cash, cash equivalents, restricted cash, and marketable securities of $988.6 million, compared with $931.3 million a year ago

** In 2025, MDGL was up 88.7%

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))